Floatz logo

ONTECIZUMAB

Testicular Lymphoma

Morphotekmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Testicular Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
University of Chicago
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 44 →

Same molecule, other indications

ONTECIZUMAB is also rated in:

metastatic melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →